BAC
Bank of America Corporation
BAC's fundamentals are strong: its operating margin rose 5 points to 35% and revenue grew 15%. At 12x earnings, it's trading in line with its usual 13x. Analysts expect earnings growth.
HCXY
Hercules Capital, Inc.
There isn't enough reported data to score HCXY yet.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
HCXY Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Healthy | |
| N/A | |
| N/A |
HCXY's profitability is currently healthy, but its revenue is under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like HCXY.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
HCXY PE Valuation
HCXY has no meaningful PE right now: it lost money over the past year.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over HCXY on the outlook, with more favorable earnings and profitability expectations.
HCXY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect HCXY's revenue to grow, but its profitability to weaken.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over HCXY on earnings, with more consistent year-over-year improvement.
HCXY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $1.88 | +9.3% |
| Q2 2026 | $2.03 | +34% |
| Q1 2026 | $1.79 | +35% |
| Q4 2025 | $1.85 | +15% |
| Q3 2025 | $1.72 | -15% |
| Q2 2025 | $1.51 | -16% |
| Q1 2025 | $1.33 | -40% |
| Q4 2024 | $1.61 | -30% |
HCXY's earnings per share have fallen from their peak: $1.88 over the past year, against $2.89 in mid-2021.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
HCXY has the stronger quarterly revenue trend. Revenue is up 6.7% for BAC versus up 52% for HCXY.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
HCXY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2022 | $87.4M | +52% |
| Q2 2022 | $21.7M | -81% |
| Q1 2022 | $29.7M | -70% |
| Q4 2021 | $40.2M | -78% |
| Q3 2021 | $57.4M | -23% |
| Q2 2021 | $115.3M | +23% |
| Q1 2021 | $98.4M | +2179% |
| Q4 2020 | $184.3M | +145% |
HCXY's revenue is recovering but still below its 2020 peak: $87M last quarter, up 52% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2022 | 61% | +20 points |
| Q2 2022 | -48% | -119 points |
| Q1 2022 | -11% | -77 points |
| Q4 2021 | 9.2% | -73 points |
| Q3 2021 | 41% | -17 points |
| Q2 2021 | 72% | +6.1 points |
| Q1 2021 | 65% | +731 points |
| Q4 2020 | 82% | +23 points |
HCXY's operating margin was 61% last quarter, up 20 points from the same quarter a year ago.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC has the edge over HCXY on cash generation, producing positive trailing cash flow while its opponent burns cash.
HCXY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$165.6M | -$162.4M |
| Q2 2026 | $297.9M | +$442.8M |
| Q1 2026 | -$230.7M | -$8.4M |
| Q4 2025 | -$55.6M | -$26.4M |
| Q3 2025 | -$3.2M | -103% |
| Q2 2025 | -$144.8M | -345% |
| Q1 2025 | -$222.2M | +$19M |
| Q4 2024 | -$29.2M | -122% |
HCXY's free cash flow was −$154M over the past year, against −$399M the year before. Free cash flow isn't a meaningful measure for financial services companies like HCXY.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over HCXY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
HCXY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +501K shares |
| 1 year | +2.9% | +5.7M shares |
| 3 years | +36% | +53M shares |
| 5 years | +72% | +83.8M shares |
| Available history | +89% | +94M shares |
HCXY has 200M diluted shares, up 2.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $693,000 |
| Q2 2026 | $819,000 |
| Q1 2026 | $3.4M |
| Q4 2025 | $1M |
| Q3 2025 | $974,000 |
| Q2 2025 | $1M |
| Q1 2025 | $3.5M |
| Q4 2024 | $1M |
HCXY spent $6M buying back its own shares over the past year, down 9.3% from the year before.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
HCXY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | 33.8x | High |
| Q2 2022 | 100.4x | High |
| Q1 2022 | 11.9x | High |
| Q4 2021 | 6.4x | High |
| Q3 2021 | 3.7x | Elevated |
| Q2 2021 | 3.4x | Elevated |
| Q1 2021 | 3.6x | Elevated |
| Q4 2020 | 4.8x | High |
HCXY's net debt is more than 20 years of its operating earnings (EBITDA), up from 3.7 years a year ago. Net leverage isn't a meaningful measure for financial services companies like HCXY.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
HCXY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.5 | Neutral |
| Stochastic | 36.7 | Neutral |
HCXY's weekly RSI is 36 (neutral) and its Stochastic is 37 (neutral).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC has the edge over HCXY on valuation relative to its sector.
HCXY PE vs Financial Services Sector
| Metric | HCXY | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 13x | 1.8% below |
| PE % | 44 | 63 | 19 pts below |
HCXY has no meaningful PE right now: it lost money over the past year.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has the edge over HCXY on trend strength, trading above more of its moving averages.
HCXY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $24.4 | 0.8% below |
| 20 week MA | $24.7 | 2.2% below |
| 50 week MA | $25.0 | 3.2% below |
| 100 week MA | $25.0 | 3.4% below |
| 200 week MA | $24.8 | 2.7% below |
HCXY is in a downtrend: it's below all five of its weekly moving averages, and 2.7% below its 200-week average.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
HCXY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.3 | $26.8 | +2% |
| 2021 | $26.8 | $26.4 | -1.5% |
| 2022 | $26.4 | $23.9 | -9.7% |
| 2023 | $23.9 | $25.3 | +5.9% |
| 2024 | $25.3 | $24.9 | -1.2% |
| 2025 | $24.9 | $25.3 | +1.5% |
| 2026 YTD | $25.3 | $24.2 | -4.5% |
HCXY has the edge over BAC on returns for 2026, with the stronger performance.